FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	OVAL					
OMB Number:	3235-0287					
Estimated average burden						
hours per response	. 0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	e Responses)																
1. Name and Address of Reporting Person * Fust Matthew K				2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)XDirector10% Owner							
(Last) (First) (Middle) C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD, SUITE 900				3. Date of Earliest Transaction (Month/Day/Year) 06/16/2020							(Officer (give	e title below)	Oth	er (specify belo	ow)		
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person							
SOUTH SAN FRANCISCO, CA 94080																		
(City	")	(State)	(Zip)		Table I - Non-Derivative Securities Acquir						ired, I	red, Disposed of, or Beneficially Owned						
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year	2A. Deemed Execution Date, i rr) any (Month/Day/Year		ate, if	(Instr. 8)		(.	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)					d	Ownership of Form:	7. Nature of Indirect Beneficial Ownership	
				(World)	Дау	/ I car)	Cod	le	V	Amount	(A) or (D)	Price				or Indirect (I) (Instr. 4)	•	
Common	Stock		06/16/2020				A			3,000 1)	A	\$ 0	0 33,854			D		
	Persons who respond to the collection of information contained SEC 1474 (9-02) in this form are not required to respond unless the form displays a currently valid OMB control number. Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Derivative Security	ivative Conversion of Date Execution Date, if Transaction of Derivative Execution Date, if Code Securities (Month/Day/Year)		6. D Expi	5. Date Exercisable and Expiration Date of Ur (Month/Day/Year) Security			7. Title of Und Securi	Inderlying Derivative Security		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Owners Form of Derivat Security Direct (or Indir	Ownershi (Instr. 4)						
				Code	V	(A)	(D)	Date Exe	e rcisable	Expira Date	ation	Title		Amount or Number of Shares		(Instr. 4)	(Instr. 4)
Non- Qualified Stock Option (Right to Buy)	\$ 10.54	06/16/2020		A		24,500			(2)	06/15	5/2030	Com: Sto		24,500	\$ 0	24,500	D	

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Fust Matthew K C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO, CA 94080	X					

Signatures

/s/ David Tucker, Attorney-in-Fact	06/17/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- These restricted stock units shall vest on the earlier of June 16, 2021 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
- (2) The option shall vest on the earlier of June 16, 2021 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.